Summit Therapeutics Inc SEC Filings

Summit Therapeutics Inc. reported that its Chief Accounting Officer, Anand Bhaskar, received a stock option grant. On January 8, 2026, Bhaskar was awarded an option to purchase 30,000 shares of Summit Therapeutics common stock at an exercise price of $18.83 per share.

The option becomes exercisable over time, vesting in four equal annual installments, with the first installment scheduled to vest on January 8, 2027. The option expires on January 8, 2036. Following this grant, Bhaskar beneficially owns 30,000 derivative securities directly in the form of this stock option.

Summit Therapeutics Inc. reports a preliminary unaudited balance of approximately $710 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing a snapshot of its available liquidity.

The company also highlights key business developments: it plans to present at the 44th Annual J.P. Morgan Healthcare Conference, has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval for ivonescimab in combination with chemotherapy for certain epidermal growth factor receptor-mutated non-small cell lung cancer patients, and has entered into a clinical trial collaboration with GSK to study ivonescimab with GSK’s investigational B7-H3 targeting antibody drug conjugate across multiple solid tumors, including small cell lung cancer.

Summit Therapeutics Inc. director Robert F. Booth reported receiving two stock option grants on January 2, 2026. He was granted stock options to purchase 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, as long as he remains a non-salaried director on each vesting date.

Booth was also granted stock options covering 7,180 shares of common stock, also at an exercise price of $17.52 per share and expiring on January 2, 2036. These options vest in four quarterly installments on March 31, June 30, September 30 and December 31 following his election as a director and were issued under the company’s Director Retainer Option Election Plan in lieu of $62,900 in retainer fees.

Summit Therapeutics Inc. reported that director Kenneth A. Clark received new stock option awards. On January 2, 2026, he was granted 35,000 stock options with an exercise price of $17.52 per share, vesting in four quarterly installments during the year of grant, as long as he continues serving as a non-salaried director on each vesting date. On the same date, he also received a separate grant of 17,796 stock options with the same exercise price, issued under the company’s Director Retainer Option Election Plan in lieu of $155,900 of cash retainer fees. All reported options are held directly.

Summit Therapeutics Inc. reported that director Alessandra Cesano received new stock option awards. On 01/02/2026, she was granted a stock option for 35,000 shares of common stock at an exercise price of $17.52 per share, expiring on 01/02/2036. These shares vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the grant year, as long as she continues serving as a non-salaried director.

She was also granted a separate stock option for 3,219 shares of common stock at the same $17.52 exercise price, expiring on 01/02/2036. This option was issued under the company’s Director Retainer Option Election Plan in lieu of cash retainer fees of $28,200 and vests in four quarterly installments on March 31, June 30, September 30 and December 31 following her election, contingent on continued board service.

Summit Therapeutics (SMMT) reported that its partner Akeso published final overall survival results from the Phase III HARMONi-A trial in China. The study tested ivonescimab plus platinum-doublet chemotherapy versus chemotherapy alone in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC after EGFR TKI therapy.

Ivonescimab plus chemotherapy achieved a statistically significant and clinically meaningful overall survival benefit with a hazard ratio of 0.74 (95% CI: 0.58, 0.95; p=0.019). Median OS was 16.8 months (95% CI: 14.5, 20.0) versus 14.1 months (95% CI: 12.8, 16.3) for chemotherapy alone. The analysis used an April 2025 data cut-off and had a 32.5‑month median follow-up. Summit furnished these data via a press release attached as Exhibit 99.1.

Summit Therapeutics (SMMT) reported an insider transaction by director Yu Xia. On 10/21/2025, she acquired 533,617 shares of common stock at $18.74 per share in a private placement pursuant to a definitive agreement, anticipated to close on or about 10/23/2025. After the transaction, 32,057,147 shares were beneficially owned indirectly through Akeso, Inc. Dr. Xia disclaims beneficial ownership of Akeso’s holdings except to the extent of her pecuniary interest.

Summit Therapeutics (SMMT) insider transaction: Chief Accounting Officer Bhaskar Anand reported acquiring 26,680 shares of common stock at $18.74 per share on 10/21/2025. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.

Following the reported transaction, Anand beneficially owned 159,751 shares directly. Holdings include shares previously acquired through the company’s employee stock purchase plan.

Summit Therapeutics Inc. (SMMT) reported an insider purchase by its COO and CFO, who is also a director. On 10/21/2025, the reporting person acquired 53,361 shares of common stock at $18.74 per share, coded as an acquisition (A).

Following this transaction, the reporting person beneficially owned 3,073,603 shares, held directly. The shares were acquired in a private placement under a definitive agreement dated October 21, 2025, with the transaction anticipated to close on or about October 23, 2025.